Effect of apixaban for anti-atherosclerotic response in atrial fibrillation patients

Effect of apixaban for anti-atherosclerotic response in atrial fibrillation patients - Effect of apixaban for anti-atherosclerotic response in atrial fibrillation patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013308

Enrollment

50

Registered

2014-03-02

Start date

2014-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Prescirbe apixaban 5mg twice daily for 6 months. Patients who correspond to low dose standard pescirbe apixaban 2.5mg twice daily.

Sponsors

Yokohama Sakae Kyosai Hospital

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: nonvalvular atrial fibrillation

Exclusion criteria

Exclusion criteria: High risk for bleeding Renal failure severe infection and trauma,perioperaion History of allergy to apixaban Ineligible in the opinion of investigators

Design outcomes

Primary

Measure	Time frame
Change of inflammatory cytokine,hs-CRP,PTX3,TM Transition of blood coagulation and fibrinolysis	—

Secondary

Measure	Time frame
Evaluation of atherosclerotic actions by ABI/CAVI Evaluation of atherosclerotic plaque volume by carotid artery echo	—

Countries

Japan

Contacts

Public ContactHiromasa Katoh

Yokohama Sakae Kyosai Hospital Division of Cardiology,Department of Internal Medicine

hiromasa_im2_m@yahoo.co.jp045-891-2171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026